UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 July 30, 2025 July 30, 2025
Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch July 29, 2025 July 29, 2025
Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation May 28, 2025 May 28, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025 May 7, 2025 May 7, 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI March 31, 2025 March 31, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder February 25, 2025 February 25, 2025
